DeZwarteRidder schreef op 30 augustus 2018 20:54:
CytoDyn receives ODD for PRO 140 for prevention of GvHD
Stock MarketsOct 05, 2017 08:42AM ET CytoDyn (OTCQB:CYDY) announces that the FDA has granted Orphan Drug designation to PRO 140 for the prevention of graft versus host disease (GvHD).
Among the benefits of Orphan Drug status in the U.S. is a seven-year period of market exclusivity for the indication, if approved.
PRO 140 is a humanized IgG4 monoclonal antibody directed against CCR5, a molecular portal that HIV uses to enter T cells.